Form 4 for RARE Ultragenyx Pharmaceutical Inc.
Accepted 2024-03-05 00:00:00 ET · period of report 2024-03-01 · accession 0000950170-24-026641 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-03-05 | 2024-03-01 | RARE | Huizenga Theodore Alan | SVP, CAO | A - Grant | $0.00 | +13.9K | 41.8K | +50% | $0 |
| D | 2024-03-05 | 2024-03-01 | RARE | Huizenga Theodore Alan | SVP, CAO | F - Tax | $53.69 | -121 | 41.7K | -0.3% | -$6,496 |
| D | 2024-03-05 | 2024-03-01 | RARE | Huizenga Theodore Alan | SVP, CAO | S - Sale | $53.76 | -341 | 41.4K | -0.8% | -$18.3K |
| DM | 2024-03-05 | 2024-03-01 | RARE | Huizenga Theodore Alan | SVP, CAO | A - Grant | $0.00 | +10.6K | 2,351 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-01 | A | A | 13,950 | $0.00 | 41,842 | D | — | — | (F1) Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date |
| 2 | Common | Common Stock | 2024-03-01 | F | D | 121 | $53.69 | 41,721 | D | — | — | (F2) Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. |
| 3 | Common | Common Stock | 2024-03-01 | S | D | 341 | $53.76 | 41,380 | D | — | — | (F3) Represents shares sold to pay required tax withholdings due to the vesting of RSUs. (F4) Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. |
| 4 | Derivative | Stock Option (Right to Buy) | 2024-03-01 | A | A | 8,200 | $0.00 | 8,200 | D | $53.69 · — to 2034-03-01 | 8,200 Common Stock | (F5) On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. |
| 5 | Derivative | Stock Option (Right to Buy) | 2024-03-01 | A | A | 2,351 | $0.00 | 2,351 | D | $67.37 · — to 2027-03-01 | 2,351 Common Stock | (F6) On March 1, 2022, the Reporting Person was granted an option to purchase 2,351 shares of common stock. The option vests upon the achievement of specified performance criteria. Upon achievement of the performance criteria, 1/3 of the option vests on the date of certification by the Issuer's compensation committee of achievement of the performance criteria, 1/3 of the option vests on March 1, 2024 and 1/3 of the option vests on March 1, 2025. On March 1, 2024, the Issuer's compensation committee certified achievement of the performance criteria for the option, resulting in the vesting of the option of 1,568 shares on that date. |